AU2001294514A1 - Anhydrous, hydrophilic absorbent wound dressing - Google Patents
Anhydrous, hydrophilic absorbent wound dressingInfo
- Publication number
- AU2001294514A1 AU2001294514A1 AU2001294514A AU2001294514A AU2001294514A1 AU 2001294514 A1 AU2001294514 A1 AU 2001294514A1 AU 2001294514 A AU2001294514 A AU 2001294514A AU 2001294514 A AU2001294514 A AU 2001294514A AU 2001294514 A1 AU2001294514 A1 AU 2001294514A1
- Authority
- AU
- Australia
- Prior art keywords
- wound dressing
- starch
- superabsorbent polymer
- superabsorbent
- wound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Description
TITLE:
ANHYDROUS, HYDROPHI IC ABSORBENT WOUND DRESSING
FIELD OF THE INVENTION
This invention relates to wound dressings, particularly those which may be packaged in a dispensing tube.
BACKGROUND OF THE INVENTION Draining wounds, such as Stage I-IV pressure ulcers, venous stasis ulcers, arterial ulcers, diabetic ulcers, donor sites, abrasions, lacerations, superficial burns, post- surgical wounds, and other external wounds, have often been a medical problem. Such wounds often contain necrotic tissue, and at the same time draining sites for blood, serum, etc. If such materials are allowed to accumulate and the wound not regularly cleaned, it is an ideal place for bacterial growth which, of course, promotes infection.
It has, of course, been recognized in the past that removal of necrotic tissue and wound exudate promotes faster healing, free from infection risk. In the past, others have attempted to formulate wound dressings containing water absorbent polymers such as starch superabsorbent polymers; however, such post compositions have met with limited commercial success.
One of the reasons believed to have been primary in this limited success is that all known past formulations have contained water. Water, when present in such formulations, reduces the viscosity, creates increased stability problems, and selectively holds water-soluble medicament actives so that they are not as easily released into wound exudate.
There is, therefore, a continuing need for improved formulations containing superabsorbent polymers which effectively allow the superabsorbent polymer to absorb wound exudate, while at the same time selectively releasing active medicaments into the wound on a gradual basis to
allow the wound to be clean, dry and infection-free. This invention has as its primary objective the fulfillment of this need.
Another objective of the present invention is to provide an anhydrous, hydrophilic absorbent wound dressing which can effectively be contained in, and dispensed from a squeeze tube dispensing container, or be impregnated on a gauze pad.
Yet another objective of the present invention is to provide an anhydrous, hydrophilic absorbent wound dressing which contains active medicaments such as antimicrobials which, when applied to the wound site from a dispensing tube, allows wound fluid to be absorbed into the anhydrous, hydrophilic base, while simultaneously displacing into the wound the antimicrobial or pharmaceutically active ingredient.
A still further objective is to provide an anhydrous, hydrophilic absorbent wound dressing which allows slow release of the pharmaceutically active to the infection wound bed while simultaneously absorbing in a superabsorbent polymer, microbial-laden watery exudate.
The method and manner of accomplishing each of the above objectives will become apparent from the detailed description of the invention which follows hereinafter.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 shows in vitro absorbency of artificial wound fluid for the absorbent base of Example 7.
SUMMARY OF THE INVENTION
An anhydrous, hydrophilic superabsorbent wound dressing, having a viscosity capable of being contained in, and expelled from a dispensing tube or impregnated on a gauze pad is prepared. It is comprised of an anhydrous, hydrophilic gel-based carrier which is either a poloxamer or a polyethylene glycol, in combination with a superabsorbent polymer and an active medicament such as an antimicrobial agent. It functions to absorb microbial-
laden exudate into the product, and simultaneously allows slow release of antimicrobial active medicament, for example, into the affected wound bed. These two events occur simultaneously because of the unique anhydrous nature of the formulation composition which allows this co-acting mechanism to occur.
DETAILED DESCRIPTION OF THE INVENTION
A unique co-action combination of the present invention allows simultaneous absorption of microbial-laden exudate from a wound while slowly releasing, for example, antimicrobial actives into the wound bed. The combination is of an anhydrous, hydrophilic gel base carrier which may be a poloxamer or polyethylene glycol with a superabsorbent polymer, which may be a starch polymer, a homopolymer, or a cellulose base superabsorbent polymer. The importance of the initial composition being anhydrous is that such is essential and critical to the consistent release of the effective concentration of the soluble active of the formulation as it interfaces with an open wound. Such is less likely to occur if the formulation initially contains water.
An anhydrous gel base carrier can be either a poloxamer gel base or a polyethylene glycol gel base. Both have been used in the past in the wound dressing environment, although in different types of formulations than those described herein.
Poloxamers are block copolymers commercially available from BASF
Corporation under the registered trade name Pluronic® and Lutrol™ F. These are described as block copolymers of ethylene oxide and propylene oxide represented by the following chemical structure:
HO(C2H4θ)χ(C3H6θ)y(C2H4θ)xH
In the above formula x and y represent whole integers controlling the molecular weight and therefore the viscosity of the polymer. Generally x is from 2 to 150, and y is from 15 to 70. Preferably x is from 12 to 141, and y is from 20 to 56. As will be evident from the examples which follow, these
poloxamers or pluronic polyols are available from BASF and are fully described in BASF available publications such as Technical Bulletin: Pluronic® Block Copolymer NF Grade (Poloxamer NF Grades), copyright 1992, available from BASF Corporation, 100 Cherry Hill Road, Parsippany, New Jersey 07054. Disclosure of this Technical Bulletin is incorporated by reference.
Generally speaking, the polyoxy ethylene portion of the polymer may vary from as little as 10 percent to as high as 85 percent. The higher the polyoxyethylene percentage, the more water-soluble becomes the total molecule or polymer. The substantially water-soluble polymers in the molecular weight range of between about 1000 and about 16,000 are preferable. These materials are readily available under the trade name Pluronic® or Lutrol™ F polyols. A preferred material of this class for use in the compositions of this invention is available under the trade name of Pluronic F68 and has an average molecular weight of about 8350, although it may vary in range between about 7680 and 9510. In this material "x" in the above formula can, for example, be 80 and "y" can be 27.
The other, or second general class of suitable gel material for the anhydrous, hydrophilic gel base carrier are generally polyols, and intended to be included within this term are polymeric ethers, polymeric aliphatic alcohols, either together or alone, and polyalkoxylated alcohols.
Polyols suitable for use in the present invention include dihydroxyalkanes such as glycols which have from 3 to 4 carbon atoms.
Polyhydroxyalkanes of the general formula
in which n is a number from 3 to 6 are suitable for the preparation of a dressing of the invention and are, for example, glycerin, sorbitol and mannitol.
A polyethylene glycol suitable as a polyol for the preparation of a dressing of the invention is a water-soluble one having a molecular weight in the range of from 200 to 8000. A polypropylene glycol that may be used is water-soluble and preferably has a molecular weight of in the range of from
400 to 4000. Such polymeric ethers and polyethylene glycols are sold by Union Carbide under the trademark Carbowax®, and generally are described in Technical Bulletin Carbowax® Polyethylene Glycols copyright 1981, which is incorporated herein by reference. The amount of base, whichever one is chosen, can be from about 25% to about 99% by weight of the wound dressing, but is preferably within the range of from about 50% to 90%. Turning next to the superabsorbent polymer, the ingredient can be a starch or non-starch superabsorbent polymer. For example, it can be a starch superabsorbent polymer or cellulose superabsorbent polymer, both with equally satisfactory results.
Graft copolymers of starch-poly aery lonitrile and non-starch homopolymers of poly aery lonitrile per se are known, as well as are methods for their preparation.
Thus, it is known that acrylonitrile can be grafted on starch using eerie salts as catalysts to form starch-acrylonitrile graft copolymers. See, for example, U.S. Pat. No. 2,922,768. Such graft copolymers can also be prepared by the reaction of acrylonitrile with preirradiated starch which is prepared by irradiation of starch with gamma rays or an electron beam. See Reyes, Clark, Comas, Russell, and Rise, Nuclear Applications 6, 509-517(1969). In such graft copolymers the starch serves as a backbone or building block on which the acrylonitrile is grafted, and therefore the starch need be present in only very small proportions with respect to the polyacrylonitrile moiety.
After the starch polyacrylonitrile graft copolymer is produced to make it valuable as a water-insoluble material having the ability to absorb large amounts of water, it is saponified. For example, U.S. Pat. No. 3,425,971 is directed to saponification of a graft copolymer in an aqueous potassium hydroxide solution.
As described in U.S. Patent 4,558,100, a non-starch homopolymer is prepared by treating an aqueous mixture of acrylonitrile (or methacrylonitrile) and a polyfunctional monomeric cross-linking agent with a polymerization initiator to achieve polymerization and cross-linking of the acrylonitrile. The
resultant cross-linked polyacrylonitrile is then saponified using an aqueous alcoholic solution of an alkali metal base, recovered by washing with an alcohol and filtering, and finally dried to obtain the solid granular superabsorbent. The non-starch homopolymer is classified as poly(2- propenamide-co-2-propenoic acid, sodium salt).
Suitable cross-linked cellulose derivatives include those of the hydroxy lower alkyl celluloses wherein the alkyl group aptly contains from 1 to 6 carbon atoms, e.g., hydroxyethylcellulose, hydroxypropylcellulose; and the carboxycelluloses e.g., carboxymethylhydroxyethylcellulose and carboxymethylcellulose.
Ionic cellulose derivatives such as the carboxy celluloses are suitable. Carboxymethylcellulose in the form of its sodium salt is a preferred cellulose derivative. It is readily available and is the cheapest form of carboxymethylcellulose. However, other salt forms may also be used, e.g., lithium and potassium.
Carboxymethylcellulose may be prepared according to conventional methods. Thus, it may be prepared by the reaction of cellulose with the sodium salt of chloroacetic acid in aqueous alkaline organic slurries. Thus, cellulose is steeped in sodium hydroxide solution, and the alkali cellulose is treated under controlled conditions with sodium monochloroacetate to form the sodium salt of carboxymethylcellulose and sodium chloride.
The carboxymethylcellulose may be cross-linked by forming chemical, e.g., ester or ether cross-linkages or thermal cross-linkages, depending on the mode of manufacture. The most preferred superabsorbent polymers are those sold by Grain
Processing Corporation, Muscatine, Iowa, under the trademark Water Lock® Superabsorbent Polymer. They are described in a grain processing Technical Bulletin, TB20-021296, with the preferred Water Lock® polymer being from the WATER LOCK® G-400 series, which is a homopolymer material classed as a Poly(2-propenamide-co-2-propenoic acid, sodium salt). It is described in Product Data sheet 081297, which also is incorporated herein by reference.
The most preferred Water-Lock is G-460. The particle size of the G-460 is smaller than the G-400 and provides for a smoother texture in the composition. The amount of the superabsorbent in the composition can vary, but will be within the general range of from 1% to 50% by weight of the total composition. Such levels have been found to give a desired absorbency rate. The preferred weight level is from 5% to 25%.
In addition to the above, the composition will, of course, contain an active medicament and may contsain structure -forming polymer ingredients. The structure -forming polymers could be present at a level of from 0% to 10%, and can include synthetic polymer materials such as polyvinylpyrrolidone or polyacrila ides. A suitable structure-forming polymer is a synthetic polymer known as Povidone. Another is Sepigel® from the Seppic Corporation. Such are used to aid in assuring a stable consistency.
The active medicament would generally be from about 0% to 20% by weight of the composition, and often it will be in combination with stabilizing preservatives such as Methylaparaben, Propylaparaben, Imide Urea or Benzyl Alcohol. For the most preferred compositions of the present invention, the active medicament will be water-soluble antimicrobial agents. Antifungal agents may be also employed, such as Miconazole Nitrate, Econazole Nitrate, and others. Likewise, antibiotics can be used such as Neomycin, Bacitracin, Polymixin, etc. The useful antimicrobials are not necessarily limited, and can be selected from the following list: Benzalkonium Chloride, Benzethonium Chloride, Benzoic Acid or salt form thereof, Benzoyl Peroxide, Benzyl Alcohol, Bispyrithione Salt, Borage Oil, Boric Acid, Cadexomer-Iodine, Camphorated Metacresol, Camphorated Phenol, Chlorhexidine Gluconate, Chlorobutanol, Cloflucarban, Dapsone, Dehydroacetic Acid or salt form thereof, Ethyl Alcohol, Eucalyptol, Extracts of Lavender Oil, Free fatty acids having from six to eighteen carbons, Glyceryl Laurate, Hexachlorophene, Hexitidine, Hexylresorcinol, Hydrogen Peroxide, Hydroxybenzoic Acids or salt forms thereof, Iodine Complexed with Phosphate Ester of Alkylaryloxy Polyethylene, Iodine Tincture, Iodine Topical Solution, Iodoquinol, Isopropyl Alcohol,
Lipacide CG, Mafenide Acetate, Magnesium Pyrithione, Menthol, Merbromin, Mercufenol Chloride, Methyl Salicylate, Methylbenzethonium Chloride, Methylparaben, Metronidazole, Metronidazole derivatives, Nitrofurazone, Nonyl Phenoxypoly Ethanol-Iodine, n-Propanol, Organic Peroxides, p-chloro- m-xylenol, Phenol, Phenoxyethanol, Phenyl Alcohol, Poloxamer-iodine complex, Povidone Iodine, PVP-Iodine, Rose Hips Oil, Salicylic Acid, Secondary Amyltricresols, Selenium sulfide, Silver or salt form thereof, Silver Sulfadiazine, Sodium Oxychlorosene, Sodium Sulfacetmide, Sorbic Acid or salt form thereof, Sulfur, Tetrachlorosalicylanilide, Thymol, Tribromsalan, Triclocarbon, Triclosan, Undecoylium Chloride-iodine Complex, Zinc
Pyrithione. In addition, antimicrobial pep tides and proteins which have recently been developed could be employed.
The above list demonstrates, as illustrated by its length, that the topically active, or pharmaceutically active is non-limiting. Its only criteria are that it be compatible with the superabsorbent polymer, and the anhydrous, hydrophilic gel base carrier, and that it be water-soluble.
The compositions of the present anhydrous absorbent wound dressing are illustrated by the following examples. These examples should be taken as illustrative, and non-limiting.
Example 1
Ingredient % w/w
Poloxamer 124 61.5
Poloxamer 338 17.0
Acrylamide/Sodium Acrylate Copolymer 20.0
(WaterLock G-460)
Povidone 0.5
Silver Sulfadiazine 1.0
Example 2
Ingredient % w/w
Poloxamer 124 60.0
Poloxamer 338 11.0
Acrylamide/Sodium Acrylate-Copolymer 20.0
(WaterLock G460)
Povidone 0.50 Mafenide Acetate 8.5
Example 3
Ingredient % w/w
Poloxamer 124 57.2
Poloxamer 338 21.7
Povidone 0.5
Acrylamide/Sodium Acrylate Copolymer 20.0
(WaterLock G460) Chlorobutanol 0.6
Example 4
Ingredient % w/w
Polyethylene Glycol 400 64.25
Polyethylene Glycol 3350 23.0
Acrylamide/Sodium Acrylate Copolymer 10.0
(WaterLock G-460)
Povidone 2.00
Metronidazole 0.75
Example 5
Ingredient % w/w
Polyethylene Glycol 400 59.42
Polyethylene Glycol 3350 27.48
Acrylamide/Sodium Acrylate Copolymer 10.0
(WaterLock G-460)
Povidone 0.85
Gelatin 2.0
Methylaparaben 0.25
Example 6
Ingredient % w/w
Propylene Glycol 84.4
Sepigel® 305 5.0
Acrylamide/Sodium Acrylate Copolymer 10.0
Chlorobutanol 0.6
Example 7
Ingredient % w/w
Poloxamer 407 14.0
Poloxamer 338 5.5
Poloxamer 124 34.25
Propylene Glycol 25.5
Acrylamide/Sodium Acrylate Copolymer 20.0 (WaterLock G0460)
Metronidazole 0.75
The formulations illustrated in 1-7 have been demonstrated as effective superabsorbent materials in the laboratory in in vitro fluid absorbent studies and in pharmaceutical ingredient stability studies. They also have been demonstrated as stable in dispensing squeeze tubes.
The results of in vitro fluid absorbency testing of the metronidazole - containing formulation provided by Example 7 are provided in Figure 1 along with contrasting results for a commercially available metronidazole carbomer- based gel used in wounds. The wound fluid absorbency is significantly greater for the formulation provided in Example 7 relative to that for the commercial metronidazole gel. The artificial wound fluid used in the testing better simulates the characteristics of natural wound fluid than distilled water or physiological saline solutions and is formulated containing: 0.2% w/v fatty acids, 4.0% w/v albumin, 2.5% w/v globulins, 0.05% w/v triglycerides dissolved in phosphate buffered saline (pH 7.5).
Claims (20)
1. An anhydrous, hydrophilic superabsorbent wound dressing of a viscosity capable of being contained in, and expelled from a dispensing tube, comprising: an anhydrous, hydrophilic gel base carrier selected from the group consisting of poloxamers and polyols; an effective amount of an antimicrobial agent; and a superabsorbent polymer.
2. The wound dressing of claim 1 wherein the poloxamers are coopolymers of ethylene oxide and propylene oxide of the structure:
HO(C2H4θ)x(C3H6θ)y(C2H4θ)xH wherein x is from 2 to 150 and y is from 15 to 70.
3. The wound dressing of claim 2 wherein x is from 12 to 141 and y is from 20 to 56.
4. The wound dressing of claim 1 wherein the polyol is a polyhydroxyalkane of the formula: wherein n is from 3 to 6.
5. The wound dressing of claim 1 wherein the superabsorbent polymer is selected from the group consisting of starch and non-starch super absorbent polymers.
6. The wound dressing of claim 5 wherein the superabsorbent polymer is a starch polymer.
7. The wound dressing of claim 5 wherein the superabsorbent polymer is a graft copolymer of starch polyacrylonitrile and non-starch homopolymers of polyacrylonitrile .
8. The wound dressing of claim 5 wherein the superabsorbent polymer is a poly(2-peropenamide-CO-2-proponoic acid sodium salt).
9. The wound dressing of claim 8 wherein the superabsorbent is from 5% by weight to 25% by weight of the composition.
10. The wound dressing of claim 9 wherein the superabsorbent is WaterLock® G-460.
11. The wound dressing of claim 1 wherein the active medicament is selected from the group consisting of a water-soluble antimicrobial agent.
12. A method of treating wounds to simultaneously absorb microbial-laden wound exudate and to slowly release an antimicrobial into the wound, comprising: applying to an external wound a treatment effective amount of a wound dressing, comprising: an anhydrous, hydrophilic gel base carrier selected from the group consisting of poloxamers and polyols; an effective amount of an antimicrobial agent, and a superabsorbent polymer.
13. The method of claim 12 wherein the poloxamers are coopolymers of ethylene oxide and propylene oxide of the structure:
HO(C H4θ)x(C3H6θ)y(C2H4O)χH wherein x is from 2 to 150 and y is from 15 to 70.
14. The method of claim 13 wherein x is from 12 to 141 and y is from 20 to 56.
15. The method of claim 12 wherein the polyol is a polyhydroxyalkane of the formula: wherein n is from 3 to 6.
16. The method of claim 12 wherein the superabsorbent polymer is selected from the group consisting of starch and non-starch super absorbent polymers.
17. The method of claim 16 wherein the superabsorbent polymer is a starch polymer.
18. The method of claim 16 wherein the superabsorbent polymer is a graft copolymer of starch polyacrylonitrile and non-starch homopolymers of polyacrylonitrile .
19. The method of claim 16 wherein the superabsorbent polymer is a poly(2- peropenamide-CO-2-proponoic acid sodium salt).
20. The method of claim 19 wherein the superabsorbent is from 5% by weight to 25% by weight of the composition.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/749,003 US6399092B1 (en) | 2000-12-27 | 2000-12-27 | Anhydrous, hydrophilic absorbent wound dressing (tube) with antimicrobials or other pharmaceutically active agents |
| US09/749,003 | 2000-12-27 | ||
| PCT/US2001/024800 WO2002051461A1 (en) | 2000-12-27 | 2001-08-08 | Anhydrous, hydrophilic absorbent wound dressing |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2001294514A1 true AU2001294514A1 (en) | 2003-01-23 |
| AU2001294514B2 AU2001294514B2 (en) | 2005-04-07 |
Family
ID=25011822
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2001294514A Ceased AU2001294514B2 (en) | 2000-12-27 | 2001-08-08 | Anhydrous, hydrophilic absorbent wound dressing |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US6399092B1 (en) |
| EP (1) | EP1345636B1 (en) |
| JP (1) | JP4162490B2 (en) |
| CN (1) | CN100342921C (en) |
| AT (1) | ATE290890T1 (en) |
| AU (1) | AU2001294514B2 (en) |
| CA (1) | CA2433082C (en) |
| DE (1) | DE60109487T2 (en) |
| ES (1) | ES2238482T3 (en) |
| HK (1) | HK1056845A1 (en) |
| MX (1) | MXPA03005849A (en) |
| WO (1) | WO2002051461A1 (en) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6774100B2 (en) * | 2000-12-06 | 2004-08-10 | Imaginative Research Associates, Inc. | Anhydrous creams, lotions and gels |
| US7060732B2 (en) * | 2000-12-12 | 2006-06-13 | Imaginative Research Associates, Inc. | Antibiotic/benzoyl peroxide dispenser |
| US20060189552A1 (en) * | 2000-12-12 | 2006-08-24 | Mohan Vishnupad | Dispenser for dispensing three or more actives |
| DE10121471A1 (en) * | 2001-05-02 | 2002-11-07 | Beiersdorf Ag | Plaster for controlled release of active agent to skin or wounds, comprising adsorbent, pressure-sensitive adhesive matrix surface-doped with active agent, e.g. dexpanthenol |
| US7303759B2 (en) * | 2001-06-22 | 2007-12-04 | The United States Of America As Represented By The Secretary Of The Army | Compositions and methods for reducing blood and fluid loss from open wounds |
| CA2497307A1 (en) * | 2002-09-12 | 2004-03-25 | Bj Services Company | Compositions for thermal insulation and methods of using the same |
| GB2393120A (en) * | 2002-09-18 | 2004-03-24 | Johnson & Johnson Medical Ltd | Compositions for wound treatment |
| US20040142019A1 (en) * | 2003-01-16 | 2004-07-22 | Xylos Corporation | Microbial-derived cellulose amorphous hydrogel wound dressing |
| US20040142020A1 (en) * | 2003-01-16 | 2004-07-22 | Healthpoint, Ltd. | Anhydrous, hydrophilic absorbent wound dressing |
| US20040241246A1 (en) * | 2003-05-20 | 2004-12-02 | Lipman Roger D. A. | Fluid absorbing adhesive paste |
| US20050079147A1 (en) * | 2003-10-14 | 2005-04-14 | Bernard Delaey | Wound healing compositions and uses |
| DE202004017465U1 (en) * | 2004-11-10 | 2005-12-15 | Riesinger, Birgit | Disposable absorbent body for connection to the skin and mucosal surfaces of the human body |
| US7542800B2 (en) | 2005-04-05 | 2009-06-02 | Cardiac Pacemakers, Inc. | Method and apparatus for synchronizing neural stimulation to cardiac cycles |
| EP1968627B1 (en) | 2005-11-18 | 2014-12-10 | Glanbia Nutritionals (Ireland) Limited | Compositions for disrupting and inhibiting reconstitution of wound biofilm |
| US8754045B2 (en) * | 2006-05-12 | 2014-06-17 | James A. Livingston | Enzymatic debridement therapy for abnormal cell proliferation |
| US20080058736A1 (en) * | 2006-08-30 | 2008-03-06 | Reshamwala Piyush J | Sharps container having absorbent pad and method of making the same |
| WO2008127287A2 (en) * | 2006-10-11 | 2008-10-23 | Biolife, L.L.C. | Materials and methods for wound treatment |
| US20090202615A1 (en) | 2007-02-19 | 2009-08-13 | Plurogen Therapeutics, Inc. | Compositions for Treating Biofilms and Methods for Using Same |
| WO2008151041A2 (en) * | 2007-05-31 | 2008-12-11 | Biolife, Llc | Materials and methods for preparation of alkaline earth ferrates from alkaline earth oxides, peroxides, and nitrates |
| FR2930158A1 (en) * | 2008-04-17 | 2009-10-23 | Clean Concepts Soc Par Actions | Use of acrylate and acrylamide copolymers for absorption of a physiological liquid from human or animal body, where the liquid is vomit, spit up, urine, blood, saliva, amniotic fluid, sweat, pus, stool and/or draining liquid |
| CN102170916A (en) * | 2008-08-28 | 2011-08-31 | 泰科保健集团有限合伙公司 | Environmentally activated compositions, articles and methods |
| US9533479B2 (en) | 2008-09-18 | 2017-01-03 | Medline Industries, Inc. | Absorbent articles having antimicrobial properties and methods of manufacturing the same |
| WO2010096595A2 (en) * | 2009-02-18 | 2010-08-26 | Quick-Med Technologies, Inc. | Superabsorbent materials comprising peroxide |
| US9717818B2 (en) | 2009-05-08 | 2017-08-01 | Medline Industries, Inc. | Absorbent articles having antimicrobial properties and methods of manufacturing the same |
| AU2010249574B2 (en) * | 2009-05-19 | 2015-05-14 | Plurogen Therapeutics, Inc. | Surface active agent compositions and methods for enhancing oxygenation, reducing bacteria and improving wound healing |
| KR20120117995A (en) | 2009-12-08 | 2012-10-25 | 헬쓰포인트, 엘티디. | Enzymatic wound debriding compositions with enhanced enzymatic activity |
| CN101982202B (en) * | 2010-11-02 | 2013-09-18 | 华东理工大学 | Medical hydrogel dressings and preparation method thereof |
| CN202590012U (en) * | 2011-01-07 | 2012-12-12 | 佛山市优特医疗科技有限公司 | High-hygroscopicity wound dressing capable of being removed integrally |
| RU2013150536A (en) | 2011-05-12 | 2015-06-20 | Смит & Невью Ортопедикс АГ | METHOD AND TOPICAL COMPOSITION FOR THE PROCESSING OF RAS, CONTAINING SEAPROSE AND ITS APPLICATION |
| GB201207617D0 (en) * | 2012-05-02 | 2012-06-13 | Systagenix Wound Man Ip Co Bv | Wound dressings |
| RU2014145270A (en) | 2012-05-11 | 2016-07-10 | Смит & Невью, Инк. | METHOD AND COMPOSITION FOR DESTRUCTION OF BACTERIAL BIOFILM |
| CA2936020A1 (en) * | 2014-01-31 | 2015-08-06 | Avent, Inc. | Hydrogel matrix having a non-uniform distribution of oxygen containing cells |
| WO2016118644A1 (en) | 2015-01-20 | 2016-07-28 | Plurogen Therapeutics, Llc | Compositions and methods of treating microbes |
| AU2016311235B2 (en) | 2015-08-24 | 2021-02-11 | Smith & Nephew, Inc. | Synergistic antibacterial activity of medium polarity oils in combination with antibacterial agents on bacterial biofilms |
| JP7127013B2 (en) | 2016-07-27 | 2022-08-29 | スミス アンド ネフュー インコーポレイテッド | Use of Thermolysin to Reduce or Remove Bacterial Biofilms from Surfaces |
| AU2017351950A1 (en) * | 2016-10-26 | 2019-05-02 | Oxy Solutions As | Formulations |
| US11413300B2 (en) | 2017-01-30 | 2022-08-16 | Smith & Nephew, Inc. | Synergistic combination of thermolysin and an antibacterial agent to reduce or eliminate bacterial biofilms from surfaces |
| WO2024226871A1 (en) * | 2023-04-27 | 2024-10-31 | Mccord Darlene E | Compositions and methods of dissolving biofilm to promote wound healing |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4226232A (en) | 1979-04-09 | 1980-10-07 | Spenco Medical Corporation | Wound dressing |
| US4376764A (en) | 1981-08-10 | 1983-03-15 | Basf Wyandotte Corporation | Silver ion gel compositions |
| ATE18995T1 (en) | 1981-09-30 | 1986-04-15 | Leipzig Arzneimittel | ABSORBENT WOUND DRESSING AND METHOD OF PRODUCTION. |
| DE3226753A1 (en) | 1982-07-14 | 1984-01-19 | Schering AG, 1000 Berlin und 4709 Bergkamen | Wound bandage to take up wound secretions |
| US4563184A (en) | 1983-10-17 | 1986-01-07 | Bernard Korol | Synthetic resin wound dressing and method of treatment using same |
| GB8607159D0 (en) | 1986-03-22 | 1986-04-30 | Smith & Nephew Ass | Pharmaceutical composition |
| US4885161A (en) * | 1987-03-11 | 1989-12-05 | Medi-Tech International Corporation | Wound dressings in gelled paste form |
| US4979946A (en) | 1987-12-14 | 1990-12-25 | The Kendall Company | Environmental absorbent dressing |
| US5064653A (en) * | 1988-03-29 | 1991-11-12 | Ferris Mfg. Co. | Hydrophilic foam compositions |
| US5013769A (en) | 1988-08-22 | 1991-05-07 | Medipro Sciences Limited | Method of making a hydrogel-forming wound dressing or skin coating material |
| US4920158A (en) | 1989-10-11 | 1990-04-24 | Medipro Sciences Limited | Hydrogel-forming wound dressing or skin coating material |
| US5662924A (en) * | 1991-03-21 | 1997-09-02 | Smith & Nephew Plc | Wound dressing |
| AU679937B2 (en) * | 1992-11-18 | 1997-07-17 | Johnson & Johnson Consumer Products, Inc. | Extrudable compositions for topical or transdermal drug delivery |
| US5902600A (en) * | 1992-12-21 | 1999-05-11 | Healthpoint, Ltd. | Hydrogel polymer wound dressing |
| US6066773A (en) | 1993-03-22 | 2000-05-23 | E. R. Squibb & Sons, Inc. | Thin film dressing with absorbent border |
| CA2132657C (en) | 1993-10-05 | 2005-12-06 | Marjory A. Kadash | Trimmable wound dressing |
| US5631301A (en) | 1994-09-27 | 1997-05-20 | Virotex Corporation | Topical antibiotic composition providing optimal moisture environment |
| EP0780407A3 (en) | 1995-12-22 | 1998-11-11 | Kuraray Co., Ltd. | Polyvinyl alcohol and gel therefrom |
| US5968001A (en) | 1996-05-14 | 1999-10-19 | Bristol-Myers Squibb Company | Wound dressings with leak prevention seal |
| US6706690B2 (en) * | 1999-06-10 | 2004-03-16 | Baxter Healthcare Corporation | Hemoactive compositions and methods for their manufacture and use |
| US6039940A (en) | 1996-10-28 | 2000-03-21 | Ballard Medical Products | Inherently antimicrobial quaternary amine hydrogel wound dressings |
-
2000
- 2000-12-27 US US09/749,003 patent/US6399092B1/en not_active Expired - Lifetime
-
2001
- 2001-08-08 WO PCT/US2001/024800 patent/WO2002051461A1/en active IP Right Grant
- 2001-08-08 ES ES01975161T patent/ES2238482T3/en not_active Expired - Lifetime
- 2001-08-08 CN CNB018214789A patent/CN100342921C/en not_active Expired - Fee Related
- 2001-08-08 JP JP2002552602A patent/JP4162490B2/en not_active Expired - Fee Related
- 2001-08-08 AT AT01975161T patent/ATE290890T1/en not_active IP Right Cessation
- 2001-08-08 DE DE60109487T patent/DE60109487T2/en not_active Expired - Lifetime
- 2001-08-08 EP EP01975161A patent/EP1345636B1/en not_active Expired - Lifetime
- 2001-08-08 CA CA002433082A patent/CA2433082C/en not_active Expired - Fee Related
- 2001-08-08 AU AU2001294514A patent/AU2001294514B2/en not_active Ceased
- 2001-08-08 MX MXPA03005849A patent/MXPA03005849A/en active IP Right Grant
-
2003
- 2003-12-02 HK HK03108780A patent/HK1056845A1/en not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US6399092B1 (en) | Anhydrous, hydrophilic absorbent wound dressing (tube) with antimicrobials or other pharmaceutically active agents | |
| AU2001294514A1 (en) | Anhydrous, hydrophilic absorbent wound dressing | |
| JP7013336B2 (en) | In situ crosslinkable polymer compositions and methods thereof | |
| AU2007329772B2 (en) | Hydrogel wound dressing and biomaterials formed in situ and their uses | |
| CA2106396C (en) | Wound dressing | |
| US20020122771A1 (en) | Spray hydrogel wound dressings | |
| JP2617260B2 (en) | Gel composition for wound treatment | |
| CA2323382C (en) | Wound dressing | |
| WO2002047737A1 (en) | Dressings for the treatment of exuding wounds | |
| WO2007007115A2 (en) | Treatment of chronic ulcerous skin lesions | |
| US6521243B2 (en) | Ionic chitosan -iodine complexes: antiseptic hydrogels and wound healing promoters | |
| US5242985A (en) | Aqueous stable complex of a strongly swellable, moderately crosslinked polyvinylpyrrolidone and iodine | |
| EP2315606A2 (en) | Formulations for a two-phase management of wound healing and dressings incorporating such formulations | |
| WO2023198086A1 (en) | Antibacterial healing-promoting functionalized dressing and preparation method therefor | |
| US20040142020A1 (en) | Anhydrous, hydrophilic absorbent wound dressing |